London Business School released a profile of Jasmine Sanghera, an incoming MBA who holds a BA in Molecular & Cell Biology from UC Berkeley and worked as Associate Director, Business Development at Oxford Nanopore Technologies. Sanghera cites LBS faculty expertise at the intersection of technology and healthcare as a key reason for matriculation. Her background signals LBS’s continued pull for candidates bridging biotech and commercialization. For research offices and technology-transfer teams, Sanghera’s trajectory underscores the MBA pipeline’s role in translating life‑science innovation into business models and investor‑readiness. Admissions and alumni relations teams should note the draw of cross‑sector faculty and the appeal that biotech commercialization expertise has for recruiting high‑potential applicants.